Most pharmacovigilance departments are resource constrained. Whether its human capital, budget, or both, the drug safety specialists within pharmaceutical companies are being asked to do a whole lot with very little.

As a small company ourselves, we at Advera Health know this pain well. We must work smarter, not harder (and then even harder!) to achieve our goals with fewer resources than larger companies.

For us, working smarter means leveraging technology to create quality solutions faster, marketing to potential customers more effectively, and managing all other aspects of a growing business more efficiently. The technologies that we leverage are designed to scale as we scale and be just as accessible to a small company like us as they are to Fortune 50 companies. That mass appeal and product-market fit is why the key solution providers we rely on like Dropbox, Slack, Amazon Web Services, and Hubspot  have become so important to our daily work at Advera – and big success stories overall.

Pharmacovigilance departments have traditionally not been so lucky.  For these mission critical groups, working smarter has too often meant outsourcing various key processes. While outsourcing certain tasks, such as case intake and processing can make sense, in certain circumstances there are more dynamic parts of the pharmacovigilance process where outsourcing falls short and can create more problems than solutions.

Modern pharmacovigilance departments are relied upon for aggregate signal detection, refinement and evaluation that support companies’ products throughout the life cycle.  When the needed resources for those tasks are outsourced the restrictions on types of reports, limitations on how data can be viewed and manipulated, and the time and cost of dealing with vendors and consultants severely restricts how the department operates and can support the organization.  And when the weight of these restrictions become too much to bear, the only choice historically has been to turn to large legacy software solutions. But this choice has significant cost and implementation consequences that can more than offset the advantages the organization was hoping to find.

Luckily, there are now scalable, flexible, and agile software and platform solutions that make signal detection and drug safety data accessible to equally scalable pharmacovigilance departments. One size doesn’t fit all and just because an organization is small, doesn’t mean they have to act small.

Evidex can help an organization of any size work smarter. 

Larger pharmaceutical companies can leverage Evidex for on-demand pooled meta-analyses from a curated database of clinical trial safety results.  Smaller pharmaceutical company can deploy Evidex to enable their medical reviewers to better characterize and evaluate a potential safety signal.  And in all cases, pharmacovigilance departments, can use Evidex to work smarter and act bigger than they may actually be.

See more in our comprehensive guide to using drug safety data. 



Topics: Pharmacovigiance 2.0

Jim Davis

Written by Jim Davis

As Executive Vice President, Jim is responsible for the commercialization strategy for Advera Health Analytics.